Skip to main content
NurExone Biologic Inc logo

NurExone Biologic Inc — Investor Relations & Filings

Ticker · NRX ISIN · CA67059R1091 LEI · 25490047UWNZ2P8ESB77 TSXV Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CA Canada
Listing TSXV NRX

About NurExone Biologic Inc

https://nurexone.com/

NurExone Biologic Inc. is a biopharmaceutical technology company specializing in the development of regenerative exosome-based therapies for Central Nervous System (CNS) injuries. The core of its business is the proprietary ExoTherapy platform, which utilizes nanosized extracellular vesicles (exosomes) as precision biological messengers and drug delivery vehicles. These exosomes are loaded with therapeutic compounds, creating nanodrugs designed to target inflamed or damaged neural tissue. A key product candidate is ExoPTEN, an siRNA sequence loaded onto exosomes, which has shown promise in regenerating and rewiring neurons in preclinical models of fully transected spinal cords. The company employs proprietary 2D and 3D production processes within its dedicated in-house bioreactor to ensure high-quality, large-scale production of potent exosomes.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the grant of a patent by the Korean Ministry of Intellectual Property. It does not contain financial statements, voting results, management changes, share transactions, or other regulatory filings like annual or interim reports. It is not an earnings release or investor presentation. It is an operational/legal update on intellectual property, which does not fit any specific category, so it falls into the fallback category: Regulatory Filings (RNS).
2026-05-19 English
News release - English.pdf
Regulatory Filings Classification · 25% confidence The document is a corporate press release announcing NurExone’s advancement to Stage 2 of an EU-backed program. It contains forward‐looking statements, company overview, quotes, and contact info but does not present financial results, management appointments, voting outcomes, regulatory forms, or detailed financial data. It is not an earnings release, annual or interim report, audit report, or any specific form filing. It falls under ‘General regulatory announcements’ and thus is classified as RNS.
2026-05-14 English
News release - English.pdf
Regulatory Filings Classification · 82% confidence The document is a corporate press release announcing the grant of an Australian patent and an upcoming scientific presentation. It contains no financial results, no earnings guidance, no board or management changes, no share issues, no dividend or voting information, and no detailed regulatory report. It is not itself an Annual Report, Interim Report, Earnings Release, or any of the specialized categories. As such, it falls into the fallback category for miscellaneous corporate announcements: Regulatory Filings (RNS).
2026-04-27 English
News release - English.pdf
Earnings Release Classification · 90% confidence The document is a press release titled “NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results,” summarizing key highlights, financial metrics (R&D expense, net loss, cash position) and corporate updates. It is an initial earnings announcement for the quarter and fiscal year, not the full annual report or MD&A. This matches the Earnings Release definition (Code: ER). FY 2025
2026-04-16 English
News release - English.pdf
Earnings Release Classification · 92% confidence The document is a corporate press release titled “Fourth Quarter and Full-Year 2025 Financial Results,” detailing NurExone’s Q4 and full-year financial performance, operational highlights, and corporate updates. It summarizes revenue, expenses, net loss, cash position, and financing activities, which aligns with a typical Earnings Release. It is not the full Annual Report or MD&A itself, nor merely an announcement that the report is available. Therefore, it is classified as an Earnings Release. FY 2025
2026-04-16 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Investor Presentation Classification · 50% confidence The document is a detailed client brochure for a structured note offering (BMO Principal-at-risk Notes) containing product features, terms, index details, and investment highlights. It is not an annual or interim financial report, earnings release, audit, management change, or regulatory notice. The closest available category is an “Investor Presentation” (IP), as it is a detailed presentation aimed at investors describing the product’s financial terms, features, and mechanics.
2026-04-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.